
FDA proposes setting a bar for weight-loss therapies; exposure to aircraft noise and heart function; Athira Pharma Inc. pays $4 million to settle false claims allegation – Morning Medical Update
Key Takeaways
- FDA's draft guidance recommends a minimum 5% weight loss for investigational obesity therapies to establish efficacy.
- Aircraft noise exposure is associated with stiffer heart muscles and increased risk of major cardiac events.
The top news stories in medicine today.
In a draft guidance released to the public for comment on Tuesday, the U.S. Food and Drug Administration (FDA) set out efficacy standards for investigational obesity therapies, recommending a minimum of 5% weight-loss for drug developers intent on establishing the efficacy of their investigational obesity candidates. Under the guidance, a drug candidate would be considered effective for long-term weight loss and management if it is able to demonstrate at least a 5% decrease in body weight compared to the control after one year of treatment.
A new study led by University College London (UCL) researchers and published in the
Athira Pharma Inc. has






